Table 3 Characteristics of CRAB-BSI patients with Cefoperazone/Sulbactam monotherapy and Cefoperazone/Sulbactam based combination therapy
|  | Cefoperazone/Sulbactam monotherapy (n = 30) | Cefoperazone/Sulbactam based combination therapy (n = 45) | P value |
|---|---|---|---|
Age (years) | 62 (21–95) | 60 (3–85) | 0.086 |
Male sex | 20 (66.7%) | 35 (77.8%) | 0.211 |
ICU admission | 21 (70.0%) | 34 (75.6%) | 0.392 |
APACHE II score | 19 (11–31) | 18 (12–31) | 0.371 |
APACHE II score < 20 | 18 (60.0%) | 30 (66.7%) |  |
APACHE II score ≥ 20 | 12 (40.0%) | 15 (33.3%) | 0.364 |
PBS | 3 (2–8) | 3 (1–6) | 0.554 |
CPIS | 6 (3–10) | 6 (4–10) | 0.969 |
28 day mortality | 12 (40.0%) | 10 (22.2%) | 0.082 |
 APACHE II score < 20 | 27.8% (5/18) | 13.3% (4/30) | 0.194 |
 APACHE II score ≥ 20 | 58.3% (7/12) | 40% (6/15) | 0.288 |
Underlying disease | |||
 hypertension | 13 (43.3%) | 10 (22.2%) | 0.046 |
 hepatitis/cirrhosis | 8 (26.7%) | 11 (24.4%) | 0.518 |
 diabetes | 6 (20.0%) | 6 (13.3%) | 0.323 |
 renal insufficiency | 4 (13.3%) | 7 (15.6%) | 0.533 |
 coronary | 2 (6.7%) | 7 (15.6%) | 0.216 |
 respiratory | 0 (0%) | 8 (17.8%) | 0.013 |
 tumor | 2 (6.7%) | 3 (6.7%) | 0.687 |
Comorbid conditions | |||
 pulmonary infection | 7 (23.3%) | 17 (37.8%) | 0.144 |
 septic shock | 2 (6.7%) | 3 (6.7%) | 0.687 |
 respiratory failure | 8 (26.7%) | 7 (15.5%) | 0.188 |
 MOF | 1 (3.3%) | 1 (2.2%) | 0.643 |
 abdominal cavity infection | 1 (3.3%) | 1 (2.2%) | 0.643 |
 stroke | 2 (6.7%) | 2 (4.4%) | 0.527 |
 gastrointestinal bleeding | 1 (3.3%) | 1 (2.2%) | 0.643 |